# A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

> **NCT04933825** · NA · UNKNOWN · sponsor: **EdiGene (GuangZhou) Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Malignancy(NHL/ALL)

## Interventions

- **BIOLOGICAL:** ET-02

## Key facts

- **NCT ID:** NCT04933825
- **Lead sponsor:** EdiGene (GuangZhou) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-20
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933825, "A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04933825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*